Larger Japanese Drug Makers Switch From Cancer Drugs To Anti-psychotics
This article was originally published in PharmAsia News
Executive Summary
Some of Japan's larger drug makers plan to compete for a piece of a growing global market for anti-psychotic drugs, switching from an emphasis on cancer treatments